文献速递消化系统肿瘤

帕博利珠单抗治疗索拉非尼经治晚期肝细胞癌的2期试验

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
PubMed 文献 · Lancet Oncol · 2018-06-03

KEYNOTE-224是一项非随机、开放标签、2期试验,纳入104例索拉非尼经治的晚期肝细胞癌患者,接受帕博利珠单抗200 mg每3周一次治疗。客观缓解率为17%(95%CI 11-26),治疗相关不良事件发生率73%,3级事件24%。帕博利珠单抗在该人群中有效且可耐受,可能成为治疗选择。

要点

  • 索拉非尼经治晚期肝细胞癌患者中,帕博利珠单抗客观缓解率为17%(95%CI 11-26)。
  • 治疗相关不良事件发生率为73%,3级事件24%,免疫介导性肝炎3%。
  • 帕博利珠单抗可能作为索拉非尼经治患者的治疗选择,正进行3期随机试验评估。

核心结论

  • 帕博利珠单抗在索拉非尼经治的晚期肝细胞癌患者中有效且可耐受,可能成为治疗选择。

研究设计与样本

  • KEYNOTE-224为非随机、多中心、开放标签、2期试验,在10个国家47个中心进行,纳入104例索拉非尼经治的晚期肝细胞癌患者。
  • 患者接受帕博利珠单抗200 mg静脉注射每3周一次,主要终点为客观缓解率(RECIST v1.1,中心评估)。

主要发现

  • 104例患者中客观缓解18例(17%;95%CI 11-26),其中完全缓解1例(1%),部分缓解17例(16%)。
  • 疾病稳定46例(44%),疾病进展34例(33%),6例(6%)未评估。
  • 治疗相关不良事件76例(73%),严重不良事件16例(15%);3级事件25例(24%),最常见为天冬氨酸氨基转移酶升高7例(7%)、丙氨酸氨基转移酶升高4例(4%)、乏力4例(4%)。
  • 发生1例(1%)4级治疗相关高胆红素血症,1例与治疗相关的溃疡性食管炎死亡;免疫介导性肝炎3例(3%),无病毒 flare 报告。

临床怎么用

  • 对于索拉非尼经治的晚期肝细胞癌患者,帕博利珠单抗可作为治疗选择之一。

局限性

  • 本研究为非随机、开放标签、2期试验,样本量有限,结果需3期随机试验进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune checkpoint blockade therapy has shown promising results in patients with advanced hepatocellular carcinoma. We aimed to assess the efficacy and safety of pembrolizumab in this patient population. METHODS: KEYNOTE-224 is a non-randomised, multicentre, open-label, phase 2 trial that is set in 47 medical centres and hospitals across ten countries. Eligible patients had pathologically confirmed hepatocellular carcinoma; had previously been treated with sorafenib and were either intolerant to this treatment or showed radiographic progression of their disease after treatment; an Eastern Cooperative Oncology Group performance status of 0-1; adequate organ function, and were Child-Pugh class A. Participants received 200 mg pembrolizumab intravenously every 3 weeks for about 2 years or until disease progression, unacceptable toxicity, patient withdrawal, or investigator decision. The primary endpoint was objective response, defined as the proportion of patients with complete or partial response in all patients who received at least one dose of pembrolizumab, which was radiologically confirmed by use of the Response Evaluation Criteria in Solid Tumors version 1.1 by central review. Safety was also assessed in all treated patients. This trial is ongoing but closed to enrolment and is registered with ClinicalTrials.gov number NCT02702414. FINDINGS: Between June 7, 2016, and Feb 9, 2017, we screened 169 patients with advanced hepatocellular carcinoma, of whom 104 eligible patients were enrolled and treated. As of data cutoff on Feb 13, 2018, 17 (16%) patients were still receiving pembrolizumab. We recorded an objective response in 18 (17%; 95% CI 11-26) of 104 patients. The best overall responses were one (1%) complete and 17 (16%) partial responses; meanwhile, 46 (44%) patients had stable disease, 34 (33%) had progressive disease, and six (6%) patients who did not have a post-baseline assessment on the cutoff date were considered not to be assessable. Treatment-related adverse events occurred in 76 (73%) of 104 patients, which were serious in 16 (15%) patients. Grade 3 treatment-related events were reported in 25 (24%) of the 104 patients; the most common were increased aspartate aminotransferase concentration in seven (7%) patients, increased alanine aminotransferase concentration in four (4%) patients, and fatigue in four (4%) patients. One (1%) grade 4 treatment-related event of hyperbilirubinaemia occurred. One death associated with ulcerative oesophagitis was attributed to treatment. Immune-mediated hepatitis occurred in three (3%) patients, but there were no reported cases of viral flares. INTERPRETATION: Pembrolizumab was effective and tolerable in patients with advanced hepatocellular carcinoma who had previously been treated with sorafenib. These results indicate that pembrolizumab might be a treatment option for these patients. This drug is undergoing further assessment in two phase 3, randomised trials as a second-line treatment in patients with hepatocellular carcinoma. FUNDING: Merck & Co, Inc.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018. PMID: 29875066. doi:10.1016/S1470-2045(18)30351-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。